Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative stereotactic radiotherapy boost with pembrolizumab versus placebo plus standard chemotherapy in HER2-negative breast cancer with poor early metabolic response
2023-504145-31-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoint: Pathologic complete response. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-504145-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504145-31-00.